

Maxim Group LLC
405 Lexington Ave
New York, NY 10174

June 13, 2017

VIA EDGAR

United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549

Re: Interpace Diagnostics Group, Inc. Registration Statement on Form S-1
(SEC File No. 333-218140)

Ladies and Gentleman:

In connection with the above referenced Registration Statement, and pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the "Act"), the undersigned, the representative of the several underwriters (the "Representative"), hereby joins in the request of Interpace Diagnostics Group, Inc. that the effective date of the above-referenced Registration Statement be accelerated so that the Registration Statement may become effective on 4:00 p.m. Eastern Time on Wednesday, June 14, 2017, or as soon as practicable thereafter.

Pursuant to Rule 460 under the Act, please be advised that during the period from June 7, 2017 to the date of this letter, the preliminary prospectus, dated June 7, 2017 (the "Preliminary Prospectus"), in connection with the Registration Statement was distributed approximately as follows:

Copies to underwriters:	20
Copies to prospective dealers:	10
Copies to prospective institutional investors:	35
Copies to prospective retail investors:	325
Total	390

Copies of the Preliminary Prospectus were available to anyone requesting the same at the offices of the underwriters.

The Representative confirms on behalf of itself and the several underwriters that they have complied with and will continue to comply with Rule 15c2-8 promulgated under the Securities Exchange Act of 1934, as amended, in connection with the above-referenced issue.

Sincerely,

MAXIM GROUP LLC

As Representative

/s/ Clifford A. Teller

By: Clifford A. Teller

Title: Executive Managing Director, Investment Banking
